Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT6 antagonists

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 1, 2011, Pages 650-662

  Liu, Kevin G ^a,b   Robichaud, Albert J ^a,b   Greenfield, Alexander A ^a   Lo, Jennifer R ^a   Grosanu, Cristina ^a   Mattes, James F ^a   Cai, Yanxuan ^a   Zhang, Guo Ming ^a   Zhang, Jean Y ^a   Kowal, Dianne M ^a   Smith, Deborah L ^a   Di, Li ^a   Kerns, Edward H ^a   Schechter, Lee E ^a   Comery, Thomas A ^a  

^a PFIZER INC   (United States)

^b LUNDBECK RESEARCH USA   (United States)

Author keywords

5 HT; 5 HT6; 5 Hydroxytryptamine; 5 Hydroxytryptamine 6; Alzheimer's disease; Cognition; Cognitive dysfunction; Cognitive impairment; Schizophrenia; Serotonin

Indexed keywords

2 (4 NITROPHENYL) 1,3 DIOXOLANE; 2 [3 (NAPHTHALENE 1 SULFONYLMETHYL) 4 NITRO PHENYL [1,3]DIOXOLANE; 3 (NAPHTHALEN 1 SULFONYL) 1H INDAZOL 5 YLAMINE; 3 (NAPHTHALEN 1 SULFONYL) 1H INDIZOLE 5 CARBALDEHYDE; 3 (NAPHTHALEN 1 SULFONYL) N (PIPERIDIN 4 YL) 1H INDAZOL 4 AMINE; 3 (NAPHTHALEN 1 SULFONYL) N (PIPERIDIN 4 YL) 1H INDAZOL 6 AMINE; 3 (NAPHTHALEN 1 YLSULFANYL) 5 NITRO 1H INDAZOLE; 3 (NAPHTHALEN 1 YLSULFONYL) N (PIPERIDIN 3 YL) 1H INDAZOL 4 AMINE; 3 (NAPHTHALEN 1 YLSULFONYL) N (PIPERIDIN 4 YL) 1H INDAZOL 7 AMINE; 3 (NAPHTHALEN 1 YLSULFONYL) N (PIPERIDIN 4 YLMETHYL) 1H INDAZOL 4 AMINE; 3 (NAPHTHALEN 1 YLSULFONYL) N (PIPERIDIN 4 YLMETHYL) 1H INDAZOL 5 AMINE; 3 (NAPHTHALEN 1 YLSULFONYL) N (PIPERIDIN 4 YLMETHYL) 1H INDAZOL 6 AMINE; 3 (NAPHTHALEN 1 YLSULFONYL) N (PIPERIDIN 4 YLMETHYL) 1H INDAZOL 7 AMINE; 3 (NAPHTHALEN 1 YLSULFONYL) N (PIPERIDIN 5 YL) 1H INDAZOL 4 AMINE; 3 (NAPHTHALEN 1 YLSULFONYL) N (PIPERIDIN 6 YL) 1H INDAZOL 6 AMINE; 3 (NAPHTHALEN 1 YLSULFONYL) N (PIPERIDIN 7 YL) 1H INDAZOL 7 AMINE; 3 (NAPTHALEN 1 SULFONYLMETHYL) 4 NITRO BENZALEHYDE; 3 IODO 5 NITRO 1H INDAZOLE; 3 METHYL N1 [3 (NAPHTHALEN 1 SULFONYL) 1H INDAZOL 5 YL] BUTANE 1,2 DIAMINE; 3 SULFONYLINDAZOLE DERIVATIVE; [3 (NAPHTHALEN 1 SULFONYL) 1H INDAZOL 5 YL]PIPERIDIN 4 YL AMINE; INDAZOLE DERIVATIVE; N [[3 NAPHTHYLSUFONYL) 1H INDAZOL] 5YL]METHYL]ETHANE 1,2 DIAMINE; N,N',N'' TRIMETHYL N' [[3 (1 NAPHTHYLSULFONYL) 1H INDAZOL 5 YL]METHYL]ETHANE 1,2 DIAMINE; N1 (3 (NAPHTHALEN 1 YLSULFONYL) 1H INDAZOL 6 YL)ETHANE 1,2 DIAMINE; N1 (3 (NAPHTHALEN 1 YLSULFONYL) 1H INDAZOL 7 YL)ETHANE 1,2 DIAMINE; N1 (3 NAPHTHALEN 1 YLSULFONYL) 1H INDAZOL 6 YL)PROPANE 1,2 DIAMINE; N1 3 (NAPHTHALENE 1 SULFONYL 1H INDAZOL 5 YL) ETHANE 1,2 DIAMINE; SEROTONIN 6 ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

HELA CELLS; HUMANS; INDAZOLES; MAGNETIC RESONANCE SPECTROSCOPY; NOOTROPIC AGENTS; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650731209     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.10.033     Document Type: Article

References (26)

1. F.J. Monsma Jr., Y. Shen, R.P. Ward, M.W. Hamblin, and D.R. Sibley Mol. Pharmacol. 43 1993 320
2. M. Ruat, E. Traiffort, J.M. Arrang, J. Tardivel-Lacombe, J. Diaz, R. Leurs, and J.C. Schwartz Biochem. Biophys. Res. Commun. 193 1993 268
3. R. Kohen, L.A. Fashingbauer, D.E.A. Heidmann, C.R. Guthrie, and M.W. Hamblin Mol. Brain Res. 90 2001 110
4. R. Kohen, M.A. Metcalf, N. Khan, T. Druck, K. Huebner, J.E. Lachowicz, H.Y. Meltzer, D.R. Sibley, B.L. Roth, and M.W. Hamblin J. Neurochem. 66 1996 47
5. A.J. Sleight, F.G. Boess, M. Bos, B. Levet-Trafit, and A. Bourson Expert Opin. Ther. Pat. 8 1998 1217
6. M. Hamon, E. Doucet, K. Lefevre, M.-C. Miquel, L. Lanfumey, R. Insausti, D. Frechilla, J. Del Rio, and D. Verge Neuropsychopharmacology 21 1999 68S
7. A. Bourson, E. Borroni, R.H. Austin, F.J. Monsma Jr., and A.J. Sleight J. Pharmacol. Exp. Ther. 274 1995 173
8. A.J. Sleight, F.J. Monsma Jr., E. Borroni, R.H. Austin, and A. Bourson Behav. Brain Res. 73 1996 245
9. D.C. Rogers, and J.J. Hagan Psychopharmacology 158 2001 114
10. M.V. King, A.J. Sleight, M.L. Woolley, I.A. Topham, C.A. Marsden, and K.C.F. Fone Neuropharmacology 47 2004 195
11. K.G. Liu, and A.J. Robichaud Drug Develop. Res. 70 2009 145
12. D. Witty, M. Ahmed, and T.T. Chuang Prog. Med. Chem. 48 2009 163
13. R.A. Glennon, U. Siripurapu, B.L. Roth, R. Kolanos, M.L. Bondarev, D. Sikazwe, M. Lee, and M. Dukat Curr. Top. Med. Chem. 10 2010 579
14. N. Johnson Christopher, M. Ahmed, and D. Miller Neil Curr. Opin. Drug Discov. Devel. 11 2008 642
15. 6 Antagonist for the Treatment of Cognitive Dysfunction Associated with Schizophrenia and Alzheimer's Disease. 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, 2010, MEDI-34.
16. R. Bernotas, S. Lenicek, S. Antane, G.M. Zhang, D. Smith, J. Coupet, B. Harrison, and L.E. Schechter Bioorg. Med. Chem. Lett. 14 2004 5499
17. F.Y. Kwong, and S.L. Buchwald Org. Lett. 4 2002 3517
18. M. Makosza, and J. Winiarski Acc. Chem. Res. 20 1987 282
19. S. Antane, R. Bernotas, Y. Li, R. McDevitt, and Y. Yan Synth. Commun. 34 2004 2443
20. G.A. Artamkina, A.A. Grinfel'd, and I.P. Beletskaya Tetrahedron Lett. 25 1984 4989
21. D.C. Cole, W.J. Lennox, S. Lombardi, J.W. Ellingboe, R.C. Bernotas, G.J. Tawa, H. Mazandarani, D.L. Smith, G. Zhang, J. Coupet, and L.E. Schechter J. Med. Chem. 48 2005 353
22. K.G. Liu, J.R. Lo, T.A. Comery, G.M. Zhang, J.Y. Zhang, D.M. Kowal, D.L. Smith, L. Di, E.H. Kerns, L.E. Schechter, and A.J. Robichaud Bioorg. Med. Chem. Lett. 19 2009 2413
23. K.G. Liu, J.R. Lo, T.A. Comery, G.M. Zhang, J.Y. Zhang, D.M. Kowal, D.L. Smith, L. Di, E.H. Kerns, L.E. Schechter, and A.J. Robichaud Bioorg. Med. Chem. Lett. 19 2009 1115
24. S.N. Haydar, H. Yun, P.M. Andrae, J. Mattes, J. Zhang, A. Kramer, D.L. Smith, C. Huselton, R. Graf, S. Aschmies, L.E. Schechter, T.A. Comery, and A.J. Robichaud J. Med. Chem. 53 2010 2521
25. R.H.P. Porter, K.R. Benwell, H. Lamb, C.S. Malcolm, N.H. Allen, D.F. Revell, D.R. Adams, and M.J. Sheardown Br. J. Pharmacol. 128 1999 13
26. Comery, T. A.; Schechter, L. E. WO Patent 2007167431.